Latest Articlesddd
Exelixis and Daiichi Sankyo launched their novel anitihypertension product Minnebro® in Japan Exelixis (EXEL) and Daiichi Sankyo (
The Stock Market The Confused and Confusing Stock Market The stock market is confused and confusing. …
Why GW Pharmaceuticals Survived the Bear Market Day The DOW Today Sinking for disputed and unfathomed …
A Great Day for Bluebird bio and Celgene Read the Clinical Trial Results for Myeloma What …
Vertex Pharmaceuticals' Product Kalydeco for CF in Young Children Good news for Vertex (VRTX) product Kalydeco® (ivacaftor) is …
Praluent's Approval Is a Big Deal The approval of the Regeneron / Sanofi supplemental biological license …
The Misleading Market? The biotech stocks continue to begin their daily trading relying on opinionated articles …
Exelixis & Aerie Have Good News Exelixis’ Good News about Cabometyx Takeda Pharmaceuticals applied to the …
About Trovagene Trovagene (TROV) is still a clinical-stage company. The precision cancer medicine approach is practicing what …
Zolgensma Findings The FDA submission of the gene therapy product Zolgensma was based on positive findings …
Novartis Has More Promising Data from Their Phase 3 Gene Therapy Trial with AveXis AveXis Inc., …
Gilead and insitro Collaborate to Discover and Develop Novel Therapies for NASH using ISH Gilead Sciences …
Conquering NASH Gilead and Novo Nordisk Conquering NASH What was Gilead Sciences' (GILD) announcement at …
Amgen and UDB Granted FDA Approval of Evenity™ Amgen (AMGN) and UCB Pharmaceuticals (
Regeneron and Alnylam Agreement Will Benefit Both So Why the Sell-Off? Regeneron Pharmacueticals Founded, and led …
The Amgen/Novartis Story In May 2018 Amgen (AMGN) & Novartis (
Prohost Letter #430 Rheumatoid Arthritis and Gilead The FINCH 1 trial: Has it reached its primary …
Sangamo’s Stock Price Soars Sangamo Therapeutics’ (SGMO) stock soared more than 52% in pre-market trading following …
The Market is Outperforming Today. There is important news today about Novartis; part of which we …
Following Seattle Genetics' (SGEN) and Astellas Pharma's announcement of positive results, from pivotal trial of the conjugated monoclonal antibody …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
